Canine 3-DAPv

A proven 3-year vaccine that offers comprehensive protection against 4 highly contagious canine viruses.

Canine Distemper Virus, Canine Adenovirus type 2, Canine Parvovirus (modified live viruses).

  • Provides broad coverage against canine distemper virus, canine adenovirus type 2 (CAV-2), and canine parvovirus (CPV)
  • Challenge studies in dogs showed 100% protection over 3 years against distemper, adenovirus type 1, and parvovirus10
  • Formulation containing CPV STRAIN 154®, able to override maternal antibodies at an early age1
  • Serologic tests demonstrated high antibody titers throughout the 3-year post-vaccination isolation period10
  • Manhattan strain of CAV-2 was used to confer protection against canine infectious hepatitis caused by canine adenovirus type 1 (CAV-1) without eliciting the adverse reactions associated with CAV-1 vaccines10
  • Protects against the commonly spread canine distemper virus
  • Protects against all field strains of CPV currently seen2
  • Prevents both infectious canine hepatitis caused by CAV-1 and infectious tracheobronchitis associated with CAV-2


Approved for the vaccination of healthy dogs for the prevention of disease caused by canine distemper virus and canine parvovirus, and as an aid in the prevention of disease caused by canine adenovirus (both infectious canine hepatitis and infectious tracheobronchitis) for up to 3 years following initial and booster vaccinations. Recommended for use in healthy dogs 7 weeks of age or older.


  • Can be safely administered to dogs as young as 7 weeks of age
  • High-titer CPV and canine distemper virus strains proven safe for dogs as young as 4 weeks of age1
  • No injection site or vaccine-related reactions reported during challenge studies


  • Initial 1 mL dose given by subcutaneous route to healthy dogs as early as 7 weeks of age
  • 1 mL booster doses given every 3 to 4 weeks until 12 weeks of age
  • Revaccination every 3 years with a single dose thereafter
  • Available in a 25 x 1 mL dose presentation


Efficacy & Comparisons

  • No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
  • First published data showing protection against CPV-2c challenge2
  • All vaccinated puppies were protected from disease
  • All control puppies developed disease and 50% died or were euthanized

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

Quick Guide to Lepto


A handy guide to protect dogs and prevent the spread of leptospirosis.

Learn More

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.

Learn More

AAHA Canine Vaccination Guidelines


In-depth information about canine vaccinations and veterinary best practices.


No items to show.